Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HPV-positive squamous cell cancer in the oropharynx (tonsil, base of tongue, soft palate, or throat wall), proven by pathology and p16 testing.
- Your cancer stage is low to intermediate: T1 to T3, and lymph nodes are N0 to N2c (no distant spread).
- Your scans show measurable tumor at the primary site or neck lymph nodes (certain limited surgery is allowed).
- Your health is strong enough to complete treatment: you feel well overall (performance status 0–1) and your blood/organ tests are adequate.
- If you can become pregnant or have sex that could lead to pregnancy, you agree to use reliable contraception during treatment and for at least 60 days after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
This trial tests whether giving less radiation after surgery is safe and effective for people with early-stage HPV-related throat cancer. It aims to reduce side effects while still controlling the cancer.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
This trial is testing a surgical approach for people with HPV-related oropharyngeal cancer that is stage I or II (but not the very smallest). The goal is to see if removing the tumor through the mouth and taking out neck lymph nodes is effective and safe. It may be an option if you are healthy enough for surgery.
Hear when a new Oropharynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.